Elicio Therapeutics Inc
Research Elicio Therapeutics Inc (ELTX) on Bullrun: market cap USD 65.92M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerELTX
- ExchangeNASDAQ
- CountryUnited States
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 65.92M
- Financial periodQ1 2026
- RevenueUSD 0
- Net income-USD 40.19M
- Free cash flow-USD 38.49M
Valuation Snapshot
latest market cap is USD 65.92M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 0 | -USD 39.57M | -USD 36.97M | n/a | -2.58 | USD 18.56M | USD 9.41M | USD 1.64M |
| FY2024 | USD 0 | -USD 51.90M | -USD 37.16M | n/a | -4.25 | USD 17.62M | USD 20.03M | -USD 11.31M |
| FY2023 | USD 0 | -USD 35.20M | -USD 32.76M | n/a | -6.96 | USD 12.89M | USD 6.92M | USD 11.37M |
| FY2022 | USD 2.30M | -USD 28.21M | -USD 22.83M | 100.0% | -89.27 | USD 6.16M | n/a | -USD 102.15M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-25 | USD 65.92M | n/a | n/a | n/a |
| 2025 | 2025-12-31 | USD 141.69M | n/a | n/a | n/a |
| 2024 | 2024-12-31 | USD 56.25M | n/a | n/a | n/a |
| 2023 | 2023-12-29 | USD 80.11M | n/a | n/a | n/a |
About Elicio Therapeutics Inc
Elicio Therapeutics, Inc., a clinical-stage biotechnology company, develops immunotherapies for the treatment of cancer. Its lead product candidate, ELI-002, is a multivalent lymph node-targeted amphiphile (AMP) peptide vaccine that is in Phase II clinical trials for seven Kirsten rat sarcoma viral oncogene homolog driver mutations.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Elicio Therapeutics Inc's market cap?
Elicio Therapeutics Inc's market capitalization is USD 65.92M.
What does Elicio Therapeutics Inc do?
Elicio Therapeutics, Inc., a clinical-stage biotechnology company, develops immunotherapies for the treatment of cancer. Its lead product candidate, ELI-002, is a multivalent lymph node-targeted amphiphile (AMP) peptide vaccine that is in Phase II clinical trials for seven Kirsten rat sarcoma viral oncogene homolog driver mutations.